Investor Alert: Robbins LLP Informs Investors of the EyePoint, Inc. Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)---- $EYPT #EYPT--EyePoint allegedly misled investors regarding the efficacy and viability of DURAVYU for the treatment of wet age-related macular degeneration.